- Elekta’s third-quarter net sales were SEK4.70 billion, below the estimate of SEK4.8 billion.
- Operating profit came in at SEK525 million, missing the forecast of SEK562 million.
- Adjusted operating profit was SEK548 million.
- Adjusted earnings per share (EPS) amounted to SEK0.94, falling short of the expected SEK1.05.
- EBITDA was recorded at SEK866 million.
- The company secured a public tender for eight linear accelerators.
- Elekta is adjusting its full-year guidance due to increased global uncertainty and anticipated lower sales in China and the U.S.
- For FY24/25, Elekta expects net sales to remain broadly stable with a lower EBIT margin compared to FY23/24.
- Previous projections anticipated mid-single-digit net sales growth and improved EBIT margin for FY24/25.
- Beyond the current fiscal year, Elekta aims for an EBIT margin of 14% or higher, supported by strong customer interest and rising demand.
- A cost-reduction initiative achieved SEK264 million in annual savings by the end of Q3, exceeding the target of SEK250 million.
- Analysts have issued 6 buy ratings, 7 hold ratings, and 7 sell ratings for the company.
“`
A look at Elekta AB Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Elekta AB, a company specializing in advanced medical products for treating neurological disorders and cancer through radiation therapy, has been assessed using Smartkarma Smart Scores. With a solid 4 in Dividend and Momentum, Elekta shows promise in rewarding its investors with steady payouts and displaying positive performance trends. While Value, Growth, and Resilience scores fall slightly lower at 3, indicating room for improvement in areas such as stock value, future expansion potential, and ability to withstand market challenges, Elekta’s overall outlook appears stable with room for growth.
Elekta AB, known for pioneering the Gamma Knife and offering a comprehensive system for stereotactic neurosurgery, operates globally in the healthcare sector. The company’s performance scores suggest a reliable investment option with consistent dividend payouts and strong market momentum, presenting opportunities for growth and resilience against adversities. Investors eyeing long-term prospects in the medical industry may find Elekta AB‘s position encouraging based on its Smartkarma Smart Scores evaluation.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
